English | Español

Horizon Therapeutics
Patient Daily | May 7, 2023

Horizon Therapeutics plc Reports First-Quarter 2023 Financial Results
Patient Daily | May 7, 2023

Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2 Trial Evaluating Daxdilimab for the Treatment of Lupus Nephritis
Patient Daily | May 7, 2023

Horizon Therapeutics plc Ranks First in Patient Centricity and Integrity by Patient Advocacy Groups According to New PatientView Survey
Patient Daily | May 7, 2023

Horizon Therapeutics plc Announces Initiation of Phase 3 Clinical Trial in Japan Evaluating TEPEZZA® (teprotumumab-trbw) in Adults with Chronic/Low Clinical Activity Score (CAS) Thyroid Eye Disease (TED)
Patient Daily | May 7, 2023

Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
Patient Daily | Apr 24, 2023

Horizon Therapeutics plc Announces UPLIZNA® (inebilizumab-cdon) Data in Neuromyelitis Optica Spectrum Disorder (NMOSD) to be Presented at the 2023 American Academy of Neurology (AAN) Annual Meeting
Patient Daily | Apr 24, 2023

Horizon Therapeutics plc and Massachusetts Institute of Technology (MIT) Solve Announce the Launch of the Third Annual Horizon Prize to Inspire Sustainable Solutions for Research and Care in the Rare Disease Community
Patient Daily | Apr 24, 2023

Horizon Therapeutics Announces Date of Irish Court Hearing to Sanction Scheme of Arrangement

Trending
+ Technology/Innovation
Patient Daily | May 8, 2025

Medfluence attends 2025 Annual Clinical Assembly as only strategic marketing firm
+ Technology/Innovation
Patient Daily | May 7, 2025

OTO Forum 2025 highlights innovation in ENT
+ Pharmaceuticals
Patient Daily | May 8, 2025

Pacific Research Institute CEO: Hospitals are leveraging 340B's 'perverse incentives to enrich themselves'
+ Pharmaceuticals
Patient Daily | May 8, 2025

National Library of Medicine says compounded drugs like GLP-1 offer tailored alternatives to FDA-approved treatments